Medicines Co.

Armin Kessler - Armin M. Kessler served as Chief Operating Officer of Hoffmann-La Roche in Basel Switzerland from 1990 to 1995. Prior to being appointed COO, he held several senior positions at Hoffmann-La Roche, including head of the pharmaceutical and diagnostic divisions of the organization. Earlier positions in his career included Director of Pharmaceutical Marketing Worldwide for Sandoz (now Novartis) and President of Sandoz KK in Tokyo. He currently serves on the board of The Medicines Company, Gen_Probe and Spectrum Pharmaceuticals (formerly Neotherapeutics) and has served on the boards of Hoffmann-La Roche, Syntex and Genentech. He received a degree in Physics and Chemistry from Pretoria University in South Africa, a degree in Chemical Engineering from the University of Cape Town, South Africa, a Juris Doctorate from Seton Hall University, New Jersey, and Dr. h.c. in Business Administration from the University of Pretoria.

Clive Meanwell has been a director since 1996. He has served as our Chief Executive Officer since August 2004, and he served as our President from August 2004 to December 2004, as our Executive Chairman from September 2001 to August 2004 and as our Chief Executive Officer and President from 1996 to September 2001. From 1995 to 1996, Dr. Meanwell was a Partner and Managing Director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including Senior Vice President from 1992 to 1995, Vice President from 1991 to 1992 and Director of Product Development from 1986 to 1991. Dr. Meanwell also serves as a director of Endo Pharmaceuticals Holdings Inc. Dr. Meanwell received an M.D. and a Ph.D. from the University of Birmingham, United Kingdom.

Michael Lytton is our Executive Vice President, Corporate and Business Development, and has served in that position since February 2009. From 2001 to 2009, he was a General Partner at Oxford Bioscience Partners, a venture capital firm. From 1993 to 2000, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of the law firm Edwards, Angell, Palmer & Dodge LLP. From 1984 to 1993, Mr. Lytton was a Junior Partner and Co-Chairman of the Biotechnology Practice of the law firm Wilmer Hale.

Glenn P. Sblendorio has been our Chief Financial Officer and Executive Vice President since March 2006. Prior to joining the Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development for the Company. From 1998 to July 2000, Mr. Sblendorio was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio’s pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio received his B.B.A. in accounting from Pace University and his M.B.A. in Finance from Fairleigh Dickinson University.

Kelli Watson has been our Senior Vice President Global Communications since October 2006. She joined MDCO in January 2006 in support of the Human Strategy function. Prior to joining us, she held various positions with Pfizer Inc, including Vice President Global Human Resources Planning (2002-2006), Vice President Human Resources and Planning for the Corporate Affairs function (1996-2002) and various other Human Resource positions throughout the organization. She was also played leadership roles in Pfizer's acquisition of both Warner-Lambert and Pharmacia, Kelli holds a BA in Psychology and Sociology from Hamline University, and a MA in Industrial Relations from the University of Minnesota.

Dr. Steinhubl is a leading interventional cardiologist and cardiovascular researcher. Prior to joining the Company, Dr. Steinhubl was an Associate Professor of Medicine and the Director of the Cardiovascular Education and Clinical Research at the University of Kentucky in Lexington for the past 4 years. Dr. Steinhubl has been the principle investigator and served on the Steering Committees for numerous large clinical trials including CREDO, STEEPLE, STRADIVARIUS, SYNERGY, and CHARISMA. His research activities have led to the publication of over 100 peer-reviewed manuscripts as well as numerous book chapters, and abstracts.

Dr. Spigelman is the Director of Research and Development for the TB Alliance. Previously, Dr. Spigelman spent a decade managing drug R&D at Knoll Pharmaceuticals (a division of BASF Pharma). As Vice President of R&D at Knoll, Dr. Spigelman directed clinical development and supervised all R&D activities from basic discovery to regulatory approval. He established global R&D processes as part of Knoll's senior R&D management team, oversaw a marked increase in US regulatory filings and approvals, and supervised joint R&D programs with pharmaceutical companies. Starting as Director of Oncology and Immunology in 1989, Dr. Spigelman became Vice President of R&D at Knoll until its acquisition by Abbott Laboratories in 2001. Dr. Spigelman received his undergraduate degree from Brown University and his medical degree from the Mt. Sinai School of Medicine where he specialized in Internal medicine and Neoplastic Diseases. Dr. Spigelman holds board certifications from the American Board of Internal Medicine, the American Board's Subspecialty Board of Medical Oncology, and the American Board of Preventive Medicine and was the recipient of the American Cancer Society Clinical Oncology Career Development Award (1985-1988).

Sylvia Metzler is a grandmother of four -- two of whom are old enough to fight and die in Iraq. As a practicing family nurse practitioner, she cares for many young people. She wants to protect them from trauma as if they were her grandkids. Sylvia has lived in North Philadelphia for fourteen years since returning from Nicaragua where she worked in a health care center for two years. She serves as president of the board of the Norris Square Neighborhood Project; co-chair of Medicines for Nicaragua; and co-chair of the Philadelphia Area Committee to Defend Health Care, which is committed to a universal single-payer health-care system. When she is not working for peace and social justice, she enjoys jogging, gardening, cooking, and hanging out with family and friends.

Leon E. Rosenberg, M.D. , has served on Hana's Board of Directors since February 2004 and has been non-executive Chairman of the Board since March 2007. Dr. Rosenberg has been a Professor in the Princeton University Department of Molecular Biology and the Woodrow Wilson School of Public and International Public Affairs since September 1997. Since July 1999, he has also been Professor Adjunct of Genetics at Yale University School of Medicine. From January 1997 to March 1998, Dr. Rosenberg served as Senior Vice President, Scientific Affairs of Bristol-Myers Squibb, and from September 1991 to January 1997, Dr. Rosenberg served as President of the Bristol-Myers Squibb Pharmaceutical Research Institute. From July 1984 to September 1991, Dr. Rosenberg was Dean of the Yale University School of Medicine. Dr. Rosenberg also serves on the Boards of Directors of Lovelace Respiratory Research Institute, Karo Bio AB, and Medicines for Malaria Venture. Dr. Rosenberg received B.A. and M.D. degrees, both summa cum laude, from the University of Wisconsin. He completed his internship and residency training in internal medicine at Columbia Presbyterian Medical Center in New York City.

Dr. Johnson joined MDPad's Board of Directors in August 2000. In July 1999, Dr. Johnson founded JSB Partners, L.P., an investment bank focusing on mergers and acquisitions, private financings and corporate alliances within the health care sector. From July 1991 to June 1999, Dr. Johnson served as a founder and managing director of MPM Capital, L.P. Dr. Johnson held academic positions at the Harvard Medical School from 1978 to 1996 and was actively involved in both basic science and clinical research at the Beth Israel Hospital and the Brigham and Women's Hospital. Dr. Johnson received both his B.A. and M.D. from the University of Alabama.